model updat incorpor script trend ahead
report
view adjust financial/market model ahead print
schedul tuesday april decreas estim neulasta
base script trend slightli increas enbrel estim
follow payor feedback continu see aimovig focu
call focu commerci payment traction vs free promo drug given
incred script growth slow
sp pt updat model assumpt
revis estim link preview note
neulasta enbrel ahead schedul report tuesday
april incorpor script trend neulasta biosimilar
competit coheru udenyca mylan fulphila impact neulasta
print reduc estim reflect biosimilar captur
demand throughout quarter demand
exit quarter vs st well rebat
volum initi analysi im script trend indic biosimilar
pegfilgrastim product repres overal market trx
basi growth biosimilar competit acceler
captur new prescript nrx share per week
end march reach high week slightli
increas enbrel estim expect in-lin quarter vs
st though continu expect season weak rebat
vs st aimovig remain atop cgrp
class volum nrx valu flat vs slight
increas compet cgrp molecul ajovi emgal call
focu mani patient manag convert
commerci reimburs prescript impact
prescript trend vs broader market well updat
on-going litig nv regain right aimovig link
vs st model top-lin revenu vs st
non-gaap opex vs st non-gaap net incom
vs st dilut non-gaap ep vs st
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view
trade appropri valu forward price-to-earnings basi vs
peer similar growth prospect discount project
revenu market product contribut
sh discount risk-adjust revenu pipelin product
contribut revenu contribut cash
contribut result price target
support sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep exhibit incom statement
compani report capit market estim
incom product total product product product cost expens non oper incom ebit non tax tax net ep ep exhibit dcf valuat
compani report capit market estim
compani report capit market estim
discount add add effect add termin businesskyprolisblincytorepathaparsabivevenityaimovigomecamtivbiosimilaroth revenuepric
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
